The evidence-based approach that doesn't require you to stop

There's a version of the substance use conversation that most people in the grey area never get to have — because the available frameworks all start from the same premise: that the goal is to stop, or to significantly reduce, or at minimum to accept that there is a problem requiring a solution.

Harm reduction starts somewhere different. It starts with where you actually are.

What harm reduction is

Harm reduction is a public health approach to substance use that prioritises reducing the negative consequences of use over eliminating use itself. It emerged from practical necessity in the 1980s — primarily in response to the HIV epidemic among people who inject drugs, where needle exchange programmes demonstrated that keeping people alive and healthier while they continued using was a meaningful and achievable goal, independent of whether they ever stopped.

The evidence base grew from there. Needle exchange, naloxone distribution, supervised consumption facilities, opioid agonist therapy, designated driver campaigns, low-alcohol product promotion — all of these are harm reduction interventions. They work not by requiring abstinence, but by reducing the harm that occurs in the real conditions of people's lives.

The harm reduction philosophy rests on a few core principles:

Abstinence is one possible goal among many. Reduction is a legitimate goal. Stability is a legitimate goal. Safer use is a legitimate goal. The absence of a commitment to abstinence doesn't preclude meaningful progress.

People are best placed to make decisions about their own lives. Harm reduction is explicitly non-coercive. It provides accurate information, practical tools, and non-judgemental support — and then respects the person's right to make their own choices.

Meeting people where they are. Harm reduction doesn't require a person to demonstrate readiness for change, accept a diagnosis, or commit to a treatment goal. It engages with people in their current situation and provides what's useful there.

The evidence that abstinence-only approaches miss most people

The abstinence-only model of substance use intervention has a structural problem that its evidence base reflects: it only reaches people who have already decided to stop. This is a small fraction of the people who use substances harmfully.

The much larger group — people in the grey area, people who aren't ready to stop, people who don't identify with addiction frameworks, people who want to understand their use without being pushed toward a conclusion — is almost entirely unserved by abstinence-based tools. They're not interested in sobriety counters. They're not going to download an app that identifies itself as a recovery tool. They're going to close the browser tab.

Harm reduction approaches reach this population. Not because they're less serious about health outcomes, but because they start from an honest acknowledgement of where people actually are. And the evidence consistently shows that engaging with people where they are — rather than requiring them to move to where the programme assumes they should be — produces better health outcomes across the population.

What ayodee does that's structurally harm reduction

The harm reduction principles map directly onto ayodee's design:

No goal required. You can use the app without setting a target. The data is useful regardless of whether you've decided to change anything. Understanding your pattern has value independent of any intention about it.

No substance excluded from logging. The app covers alcohol, cannabis, stimulants, opioids, benzodiazepines, and performance-enhancing substances. Logging any of these provides the same self-monitoring benefit. The user who logs their MDMA use on a Saturday night is receiving the same therapeutic mechanism — observation, awareness, pattern visibility — as the user who logs their wine.

No judgement on quantity. The app doesn't generate warnings when consumption is logged above a threshold. It doesn't flag "high risk" in a way that's designed to shame or alarm. It records what happened, accurately, and shows the pattern over time.

No labels required. You don't have to decide whether you have a problem to use the tool. You don't have to identify as a problem drinker, or a drug user, or someone in recovery. You can simply be someone who is curious about their patterns.

Information rather than prescription. The assessments (AUDIT, DAST, DASS-21) provide normative context — here's what your score means, here's the range. They don't tell you what to do with that information. The interpretation is yours.

The population-level argument

Harm reduction has always been strongest as a population-level argument. A tool that reaches 10% of heavy drinkers and produces substantial change in that group may produce less total health benefit than a tool that reaches 70% of the grey-area population and produces modest change in most of them.

The arithmetic of public health favours approaches that engage the many over approaches that intensively treat the few who were already ready to engage with intensive treatment.

Ayodee sits in the 70% population, not the 10%. It's not designed for people in crisis or people seeking recovery — there are better tools for those people. It's designed for the much larger group who are in the grey area, who aren't sure what they want to do, who just want to understand themselves better. The harm reduction framework is what makes that population accessible, and what makes the tool they use match where they actually are.

ayodee doesn't require a goal, a diagnosis, or a decision. It requires only that you log — and the evidence shows that logging alone is enough. Anonymous, no account needed.

References Marlatt, G.A. (1998). Harm Reduction: Pragmatic Strategies for Managing High-Risk Behaviors. Guilford Press.

MacCoun, R.J. (1998). Toward a psychology of harm reduction. American Psychologist, 53(11), 1199.

Ritter, A., & Cameron, J. (2006). A review of the efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit drugs. Drug and Alcohol Review, 25(6), 611–624.